About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
989
JPY
+47
(+4.99%)
Apr 10, 3:30 pm JST
6.73
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
987.3
Apr 10, 3:16 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.25
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:09 am
1,002 JPY 6.80 USD
Previous Close Apr 9
942 JPY 6.47 USD
High Apr 10, 9:10 am
1,003 JPY 6.82 USD
Low Apr 10, 9:23 am
967 JPY 6.56 USD
Volume
193,700
Trading Value
0.19B JPY 1.30M USD
VWAP
985.25 JPY 6.72 USD
Minimum Trading Value
98,900 JPY 673 USD
Market Cap
8.09B JPY 0.06B USD
Number of Trades
718
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Slightly High
1-Year Average
663
1-Year High Feb 13, 2025
14,682
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 1,005,100
Mar 28, 2025 100 1,098,400 10984.00
Mar 21, 2025 0 915,400
Mar 14, 2025 0 862,900
Mar 7, 2025 0 879,300
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.